Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Tg Therapeutics (TGTX) over the last 16 years, with Dec 2024 value amounting to $87.0 million.

  • Tg Therapeutics' Net Cash Flow fell 148.74% to -$55.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$121.7 million, marking a year-over-year decrease of 370.86%. This contributed to the annual value of $87.0 million for FY2024, which is 1029.31% up from last year.
  • Per Tg Therapeutics' latest filing, its Net Cash Flow stood at $87.0 million for FY2024, which was up 1,029.31% from -$9.4 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Net Cash Flow registered a high of $440.8 million during FY2020, and its lowest value of -$254.5 million during FY2021.
  • Its 3-year average for Net Cash Flow is -$39.7 million, with a median of -$9.4 million in 2023.
  • In the last 5 years, Tg Therapeutics' Net Cash Flow tumbled by 157.75% in 2021 and then skyrocketed by 1,029.31% in 2024.
  • Tg Therapeutics' Net Cash Flow (Yearly) stood at $440.8 million in 2020, then plummeted by 157.75% to -$254.5 million in 2021, then climbed by 22.77% to -$196.6 million in 2022, then soared by 95.24% to -$9.4 million in 2023, then skyrocketed by 1,029.31% to $87.0 million in 2024.